928,593 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Spruce Street Capital LP

Spruce Street Capital LP bought a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 928,593 shares of the company’s stock, valued at approximately $4,322,600,000. Lexeo Therapeutics accounts for approximately 0.8% of Spruce Street Capital LP’s investment portfolio, making the stock its 26th biggest position.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Lexeo Therapeutics in the second quarter worth $26,717,000. RA Capital Management L.P. purchased a new stake in Lexeo Therapeutics in the 4th quarter worth $49,650,000. Paradigm Biocapital Advisors LP bought a new position in shares of Lexeo Therapeutics during the 4th quarter valued at about $47,299,000. Balyasny Asset Management L.P. bought a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at about $16,117,000. Finally, Avoro Capital Advisors LLC purchased a new position in shares of Lexeo Therapeutics during the fourth quarter valued at about $32,769,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. dropped their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, June 25th. Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Wall Street Zen downgraded Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $18.75.

Lexeo Therapeutics Stock Up 0.8%

LXEO stock opened at $4.92 on Tuesday. Lexeo Therapeutics, Inc. has a 52 week low of $3.99 and a 52 week high of $10.99. The company has a fifty day simple moving average of $4.73 and a two-hundred day simple moving average of $5.51. The firm has a market capitalization of $403.69 million, a P/E ratio of -4.28 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). As a group, analysts anticipate that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current year.

Insider Transactions at Lexeo Therapeutics

In related news, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the transaction, the insider owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the transaction, the chief executive officer owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. This represents a 6.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 66,326 shares of company stock valued at $299,817. 2.00% of the stock is owned by insiders.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.